138. Kurakula, K.; Hamers, A.A.J.; de Waard, V.; de Vries, C.J.M. Nuclear Receptors in atherosclerosis: A superfamily with many 'Good-fellas'. *Mol. Cell Endocrinol.* **2013**, *368*, 71–84. [CrossRef]

139. Neels, J.G.; Hassen-Khodja, R.; Chinetti, G. Nuclear receptors in abdominal aortic aneurysms. *Atherosclerosis* **2020**, *297*, 87–95.
[CrossRef] [PubMed]

140. Duez, H.; Pourcet, B. Nuclear Receptors in the Control of the NLRP3 Inflammasome Pathway. *Front. Endocrinol.* **2021**, *12*, 9.
[CrossRef] [PubMed]

141. Fontaine, C.; Rigamonti, E.; Pourcet, B.; Duez, H.; Duhem, C.; Fruchart, J.C.; Chinetti-Gbaguidi, G.; Staels, B. The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. *Mol. Endocrinol.* **2008**, *22*, 1797–1811. [CrossRef]

142. Yin, L.; Wu, N.; Curtin, J.C.; Qatanani, M.; Szwergold, N.R.; Reid, R.A.; Waitt, G.M.; Parks, D.J.; Pearce, K.H.; Wisely, G.B.; et al. Rev-erb, a Heme Sensor That Coordinates Metabolic and Circadian Pathways. *Science* **2007**, *318*, 1786–1789. [CrossRef] [PubMed]

143. Dierickx, P.; Emmett, M.J.; Jiang, C.; Uehara, K.; Liu, M.; Adlanmerini, M.; Lazar, M.A. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 12147–12152. [CrossRef] [PubMed]

144. Trump, R.P.; Bresciani, S.; Cooper, A.W.; Tellam, J.P.; Wojno, J.; Blaikley, J.; Orband-Miller, L.A.; Kashatus, J.A.; Boudjelal, M.; Dawson, H.C.; et al. Optimized chemical probes for REV-ERBalpha. *J. Med. Chem.* **2013**, *56*, 4729–4737. [CrossRef]

145. Banerjee, S.; Wang, Y.; Solt, L.A.; Griffett, K.; Kazantzis, M.; Amador, A.; El-Gendy, B.M.; Huitron-Resendiz, S.; Roberts, A.J.; Shin, Y.; et al. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. *Nat. Commun.* **2014**, *5*, 5759. [CrossRef] [PubMed]

146. Pariollaud, M.; Gibbs, J.; Hopwood, T.; Brown, S.; Begley, N.; Vonslow, R.; Poolman, T.; Guo, B.; Saer, B.; Jones, D.H.; et al. Circadian clock component REV-ERBalpha controls homeostatic regulation of pulmonary inflammation. *J. Clin. Investig.* **2018**, *128*, 2281–2296. [CrossRef]

147. Marciano, D.P.; Chang, M.R.; Corzo, C.A.; Goswami, D.; Lam, V.Q.; Pascal, B.D.; Griffin, P.R. The Therapeutic Potential of Nuclear Receptor Modulators for Treatment of Metabolic Disorders: PPARγ, RORs, and Rev-erbs. *Cell Metab.* **2014**, *19*, 193–208. [CrossRef] [PubMed]

148. Duez, H.; Staels, B. Rev-erb-α: An integrator of circadian rhythms and metabolism. *J. Appl. Physiol.* **2009**, *107*, 1972–1980.
[CrossRef]

149. Kojetin, D.J.; Burris, T.P. REV-ERB and ROR nuclear receptors as drug targets. *Nat. Rev. Drug Discov.* **2014**, *13*, 197–216. [CrossRef] [PubMed]

150. Duez, H.; van der Veen, J.N.; Duhem, C.; Pourcet, B.; Touvier, T.; Fontaine, C.; Derudas, B.; Baugé, E.; Havinga, R.; Bloks, V.W.; et al. Regulation of bile acid synthesis by the nuclear receptor Rev-eralpha. *Gastroenterology* **2008**, *135*, 689–698. [CrossRef] [PubMed]

151. Vu-Dac, N.; Gervois, P.; Grotzinger, T.; Vos, P.D.; Schoonjans, K.; Fruchart, J.C.; Auwerx, J.; Mariani, J.; Tedgui, A.; Staels, B. Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalpha. *J. Biol. Chem.* **1997**, *272*, 22401–22404. [CrossRef] [PubMed]

152. Raspe, E.; Duez, H.; Mansen, A.; Fontaine, C.; Fievet, C.; Fruchart, J.C.; Vennström, B.; Staels, B. Identification of Rev-eralpha as a physiological repressor of apoC-III gene transcription. *J. Lipid Res.* **2002**, *43*, 2172–2179. [CrossRef] [PubMed]

153. Coste, H.; Rodríguez, J.C. Orphan Nuclear Hormone Receptor Rev-erbα Regulates the Human Apolipoprotein CIII Promoter. *J. Biol. Chem.* **2002**, *277*, 27120–27129. [CrossRef] [PubMed]

154. Jia, X.; Rifai, M.A.; Hussain, A.; Martin, S.; Agarwala, A.; Virani, S.S. Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. *Curr. Atheroscler. Rep.* **2020**, *22*, 72. [CrossRef]

155. Raspe, E.; Duez, H.; Gervois, P.; Fievet, C.; Fruchart, J.C.; Besnard, S.; Mariani, J.; Tedgui, A.; Staels, B. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. *J. Biol. Chem.* **2001**, *276*, 2865–2871. [CrossRef] [PubMed]

156. Gibbs, J.E.; Blaikley, J.; Beesley, S.; Matthews, L.; Simpson, K.D.; Boyce, S.H.; Farrow, S.N.; Else, K.J.; Singh, D.; Ray, D.W.; et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 582–587. [CrossRef]

157. Pourcet, B.; Zecchin, M.; Ferri, L.; Beauchamp, J.; Sitaula, S.; Billon, C.; Delhaye, S.; Vanhoutte, J.; Mayeuf-Louchart, A.; Thorel, Q.; et al. Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice. *Gastroenterology* **2018**, *154*, 1449–1464. [CrossRef]

158. Delerive, P.; Monte, D.; Dubois, G.; Trottein, F.; Fruchart-Najib, J.; Mariani, J.; Fruchart, J.; Staels, B. The orphan nuclear receptor RORα is a negative regulator of the inflammatory response. *EMBO Rep.* **2001**, *2*, 42–48. [CrossRef]

159. Billon, C.; Murray, M.H.; Avdagic, A.; Burris, T.P. RORγ regulates the NLRP3 inflammasome. *J. Biol. Chem.* **2019**, *294*, 10–19.
[CrossRef] [PubMed]

160. Duewell, P.; Kono, H.; Rayner, K.J.; Sirois, C.M.; Vladimer, G.; Bauernfeind, F.G.; Abela, G.S.; Franchi, L.; Nuñez, G.; Schnurr, M.; et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* **2010**, *464*, 1357–1361.
[CrossRef]
138. Kurakula, K.; Hamers, A.A.J.; de Waard, V.; de Vries, C.J.M. Nuclear Receptors in atherosclerosis: A superfamily with many 'Good-fellas'. *Mol. Cell Endocrinol.* **2013**, *368*, 71–84. [CrossRef]

139. Neels, J.G.; Hassen-Khodja, R.; Chinetti, G. Nuclear receptors in abdominal aortic aneurysms. *Atherosclerosis* **2020**, *297*, 87–95. [CrossRef] [PubMed]

140. Duez, H.; Pourcet, B. Nuclear Receptors in the Control of the NLRP3 Inflammasome Pathway. *Front. Endocrinol.* **2021**, *12*, 9. [CrossRef] [PubMed]

141. Fontaine, C.; Rigamonti, E.; Pourcet, B.; Duez, H.; Duhem, C.; Fruchart, J.C.; Chinetti-Gbaguidi, G.; Staels, B. The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. *Mol. Endocrinol.* **2008**, *22*, 1797–1811. [CrossRef]

142. Yin, L.; Wu, N.; Curtin, J.C.; Qatanani, M.; Szwergold, N.R.; Reid, R.A.; Waitt, G.M.; Parks, D.J.; Pearce, K.H.; Wisely, G.B.; et al. Rev-erb, a Heme Sensor That Coordinates Metabolic and Circadian Pathways. *Science* **2007**, *318*, 1786–1789. [CrossRef] [PubMed]

143. Dierickx, P.; Emmett, M.J.; Jiang, C.; Uehara, K.; Liu, M.; Adlanmerini, M.; Lazar, M.A. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 12147–12152. [CrossRef] [PubMed]

144. Trump, R.P.; Bresciani, S.; Cooper, A.W.; Tellam, J.P.; Wojno, J.; Blaikley, J.; Orband-Miller, L.A.; Kashatus, J.A.; Boudjelal, M.; Dawson, H.C.; et al. Optimized chemical probes for REV-ERBalpha. *J. Med. Chem.* **2013**, *56*, 4729–4737. [CrossRef]

145. Banerjee, S.; Wang, Y.; Solt, L.A.; Griffett, K.; Kazantzis, M.; Amador, A.; El-Gendy, B.M.; Huitron-Resendiz, S.; Roberts, A.J.; Shin, Y.; et al. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. *Nat. Commun.* **2014**, *5*, 5759. [CrossRef] [PubMed]

146. Pariollaud, M.; Gibbs, J.; Hopwood, T.; Brown, S.; Begley, N.; Vonslow, R.; Poolman, T.; Guo, B.; Saer, B.; Jones, D.H.; et al. Circadian clock component REV-ERBalpha controls homeostatic regulation of pulmonary inflammation. *J. Clin. Investig.* **2018**, *128*, 2281–2296. [CrossRef]

147. Marciano, D.P.; Chang, M.R.; Corzo, C.A.; Goswami, D.; Lam, V.Q.; Pascal, B.D.; Griffin, P.R. The Therapeutic Potential of Nuclear Receptor Modulators for Treatment of Metabolic Disorders: PPARγ, RORs, and Rev-erbs. *Cell Metab.* **2014**, *19*, 193–208. [CrossRef] [PubMed]

148. Duez, H.; Staels, B. Rev-erb-α: An integrator of circadian rhythms and metabolism. *J. Appl. Physiol.* **2009**, *107*, 1972–1980. [CrossRef]

149. Kojetin, D.J.; Burris, T.P. REV-ERB and ROR nuclear receptors as drug targets. *Nat. Rev. Drug Discov.* **2014**, *13*, 197–216. [CrossRef] [PubMed]

150. Duez, H.; van der Veen, J.N.; Duhem, C.; Pourcet, B.; Touvier, T.; Fontaine, C.; Derudas, B.; Baugé, E.; Havinga, R.; Bloks, V.W.; et al. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. *Gastroenterology* **2008**, *135*, 689–698. [CrossRef] [PubMed]

151. Vu-Dac, N.; Gervois, P.; Grotzinger, T.; Vos, P.D.; Schoonjans, K.; Fruchart, J.C.; Auwerx, J.; Mariani, J.; Tedgui, A.; Staels, B. Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalpha. *J. Biol. Chem.* **1997**, *272*, 22401–22404. [CrossRef] [PubMed]

152. Raspe, E.; Duez, H.; Mansen, A.; Fontaine, C.; Fievet, C.; Fruchart, J.C.; Vennström, B.; Staels, B. Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. *J. Lipid Res.* **2002**, *43*, 2172–2179. [CrossRef] [PubMed]

153. Coste, H.; Rodríguez, J.C. Orphan Nuclear Hormone Receptor Rev-erbα Regulates the Human Apolipoprotein CIII Promoter. *J. Biol. Chem.* **2002**, *277*, 27120–27129. [CrossRef] [PubMed]

154. Jia, X.; Rifai, M.A.; Hussain, A.; Martin, S.; Agarwala, A.; Virani, S.S. Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. *Curr. Atheroscler. Rep.* **2020**, *22*, 72. [CrossRef]

155. Raspe, E.; Duez, H.; Gervois, P.; Fievet, C.; Fruchart, J.C.; Besnard, S.; Mariani, J.; Tedgui, A.; Staels, B. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. *J. Biol. Chem.* **2001**, *276*, 2865–2871. [CrossRef] [PubMed]

156. Gibbs, J.E.; Blaikley, J.; Beesley, S.; Matthews, L.; Simpson, K.D.; Boyce, S.H.; Farrow, S.N.; Else, K.J.; Singh, D.; Ray, D.W.; et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 582–587. [CrossRef]

157. Pourcet, B.; Zecchin, M.; Ferri, L.; Beauchamp, J.; Sitaula, S.; Billon, C.; Delhaye, S.; Vanhoutte, J.; Mayeuf-Louchart, A.; Thorel, Q.; et al. Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice. *Gastroenterology* **2018**, *154*, 1449–1464. [CrossRef]

158. Delerive, P.; Monte, D.; Dubois, G.; Trottein, F.; Fruchart-Najib, J.; Mariani, J.; Fruchart, J.; Staels, B. The orphan nuclear receptor RORα is a negative regulator of the inflammatory response. *EMBO Rep.* **2001**, *2*, 42–48. [CrossRef]

159. Billon, C.; Murray, M.H.; Avdagic, A.; Burris, T.P. RORγ regulates the NLRP3 inflammasome. *J. Biol. Chem.* **2019**, *294*, 10–19. [CrossRef] [PubMed]

160. Duewell, P.; Kono, H.; Rayner, K.J.; Sirois, C.M.; Vladimer, G.; Bauernfeind, F.G.; Abela, G.S.; Franchi, L.; Nuñez, G.; Schnurr, M.; et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* **2010**, *464*, 1357–1361. [CrossRef]
161. van der Heijden, T.; Kritikou, E.; Venema, W.; van Duijn, J.; van Santbrink, P.J.; Slütter, B.; Foks, A.C.; Bot, I.; Kuiper, J. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report. *Arterioscler. Thromb. Vasc. Biology* **2017**, *37*, 1457–1461. [CrossRef]

162. Sheedy, F.; Grebe, A.; Rayner, K.; Kalantari, P.; Ramkhelawon, B.; Carpenter, S.B.; Becker, C.E.; Ediriweera, H.N.; Mullick, A.; Golenbock, D.T.; et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. *Nat. Immunol.* **2013**, *14*, 812–820. [CrossRef] [PubMed]

163. Stewart, C.R.; Stuart, L.M.; Lacy-Hulbert, A.; El Khoury, J.; Golenbock, D.T.; Moore, K.J.; Wilkinson, K.; van Gils, J.M.; Deng, J.; Halle, A.; et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. *Nat. Immunol.* **2010**, *11*, 155–161. [CrossRef]

164. Wang, S.; Lin, Y.; Yuan, X.; Li, F.; Guo, L.; Wu, B. REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis. *Nat. Commun.* **2018**, *9*, 4246. [CrossRef]

165. Yu, D.; Fang, X.; Xu, Y.; Xiao, H.; Huang, T.; Zhang, Y.; Ge, Y.; Li, Y.; Zong, L.; Gao, J. Rev-erbα can regulate the NF-κB/NALP3 pathway to modulate lipo-polysaccharide-induced acute lung injury and inflammation. *Int. Immunopharmacol.* **2019**, *73*, 312–320. [CrossRef]

166. Woldt, E.; Sebti, Y.; Solt, L.A.; Duhem, C.; Lancel, S.; Eeckhoute, J.; Hesselink, M.K.C.; Paquet, C.; Delhaye, S.; Shin, Y.; et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. *Nat. Med.* **2013**, *19*, 1039–1046. [CrossRef] [PubMed]

167. Lin, Y.; Wang, S.; Gao, L.; Zhou, Z.; Yang, Z.; Lin, J.; Ren, S.; Xing, H.; Wu, B. Oscillating lncRNA Platr4 regulates NLRP3 inflammasome to ameliorate nonalcoholic steatohepatitis in mice. *Theranostics* **2021**, *11*, 426–444. [CrossRef] [PubMed]

168. Wang, S.; Lin, Y.; Li, F.; Qin, Z.; Zhou, Z.; Gao, L.; Yang, Z.; Wang, Z.; Wu, B. An NF-κB-driven lncRNA orchestrates colitis and circadian clock. *Sci. Adv.* **2020**, *6*, eabb5202. [CrossRef] [PubMed]

169. Sulli, G.; Manoogian, E.N.; Taub, P.R.; Panda, S. Training the Circadian Clock, Clocking the Drugs, and Drugging the Clock to Prevent, Manage, and Treat Chronic Diseases. *Trends Pharmacol. Sci.* **2018**, *39*, 812–827. [CrossRef]
161. van der Heijden, T.; Kritikou, E.; Venema, W.; van Duijn, J.; van Santbrink, P.J.; Slütter, B.; Foks, A.C.; Bot, I.; Kuiper, J. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report. *Arterioscler. Thromb. Vasc. Biology* **2017**, *37*, 1457–1461. [CrossRef]

162. Sheedy, F.; Grebe, A.; Rayner, K.; Kalantari, P.; Ramkhelawon, B.; Carpenter, S.B.; Becker, C.E.; Ediriweera, H.N.; Mullick, A.; Golenbock, D.T.; et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. *Nat. Immunol.* **2013**, *14*, 812–820. [CrossRef] [PubMed]

163. Stewart, C.R.; Stuart, L.M.; Lacy-Hulbert, A.; El Khoury, J.; Golenbock, D.T.; Moore, K.J.; Wilkinson, K.; van Gils, J.M.; Deng, J.; Halle, A.; et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. *Nat. Immunol.* **2010**, *11*, 155–161. [CrossRef]

164. Wang, S.; Lin, Y.; Yuan, X.; Li, F.; Guo, L.; Wu, B. REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis. *Nat. Commun.* **2018**, *9*, 4246. [CrossRef]

165. Yu, D.; Fang, X.; Xu, Y.; Xiao, H.; Huang, T.; Zhang, Y.; Ge, Y.; Li, Y.; Zong, L.; Gao, J. Rev-erbα can regulate the NF-κB/NALP3 pathway to modulate lipo-polysaccharide-induced acute lung injury and inflammation. *Int. Immunopharmacol.* **2019**, *73*, 312–320. [CrossRef]

166. Woldt, E.; Sebti, Y.; Solt, L.A.; Duhem, C.; Lancel, S.; Eeckhout, J.; Hesselink, M.K.C.; Paquet, C.; Delhaye, S.; Shin, Y.; et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. *Nat. Med.* **2013**, *19*, 1039–1046. [CrossRef] [PubMed]

167. Lin, Y.; Wang, S.; Gao, L.; Zhou, Z.; Yang, Z.; Lin, J.; Ren, S.; Xing, H.; Wu, B. Oscillating lncRNA Platr4 regulates NLRP3 inflammasome to ameliorate nonalcoholic steatohepatitis in mice. *Theranostics* **2021**, *11*, 426–444. [CrossRef] [PubMed]

168. Wang, S.; Lin, Y.; Li, F.; Qin, Z.; Zhou, Z.; Gao, L.; Yang, Z.; Wang, Z.; Wu, B. An NF-κB-driven lncRNA orchestrates colitis and circadian clock. *Sci. Adv.* **2020**, *6*, eabb5202. [CrossRef] [PubMed]

169. Sulli, G.; Manoogian, E.N.; Taub, P.R.; Panda, S. Training the Circadian Clock, Clocking the Drugs, and Drugging the Clock to Prevent, Manage, and Treat Chronic Diseases. *Trends Pharmacol. Sci.* **2018**, *39*, 812–827. [CrossRef]